ARGX Vyvgart Myositis Win: $12B Indication With a Catch

argenx (ARGX) closed August 20 at $1,038.12, up 22% from the $851.29 it fetched the Friday before its Phase 3 ALKIVIA readout. For a $64.6 billion company, that is an $11.7 billion vote of confidence in a 175-patient trial. The market is saying myositis is a real fourth indication for Vyvgart. The market is half right. The immune-mediated necrotizing myopathy (IMNM) result is a genuine, franchise-defining win. The dermatomyositis (DM) miss is the catch the headline skipped.

What ALKIVIA Actually Showed

The Phase 3 ALKIVIA trial (NCT05523167) tested subcutaneous efgartigimod (Vyvgart Hytrulo) in adults with autoimmune myositis, and it hit its primary endpoint. At Week 52, efgartigimod produced a 15.4-point greater improvement in mean Total Improvement Score (TIS) versus placebo (47.95 vs 32.56, p=0.0011). In the prespecified IMNM subgroup, the drug delivered a 14.8-point edge (45.05 vs 30.24, p=0.0048). The DM subgroup showed a clinically similar 14.5-point improvement (51.51 vs 36.96), but with a p-value of 0.1093 it missed statistical significance in a smaller cohort.

Two of three analyses met the bar. One did not. That nuance matters more than the combined p-value, because IMNM and DM are different diseases with different competitive fields.

A 15-point TIS difference is a large effect. TIS aggregates six measures of muscle strength, function, and enzymes, and argenx also reported that 69.1% of treated patients achieved at least a 2-point TIS response. Up to 80% of myositis patients report long-term disability despite current treatment, and IMNM has no approved therapy at all. Against that backdrop, a 15-point improvement is a drug doing something real, not statistical noise.

The Catch: argenx Won IMNM, Not DM

The cleanest evidence is in IMNM, and that is by design. IMNM is the subtype with the highest unmet need and zero approved drugs, so it is also the easiest place to show a placebo delta. DM is the larger, more commercially important population, and it is about to get crowded.

This is where argenx’s own numbers matter more than the press release framing. The DM cohort missed significance at p=0.1093. That is not a near miss; it is a miss. argenx will almost certainly file the myositis sBLA on the back of the combined and IMNM results, but a label that covers IMNM alone is a smaller prize than one that covers both subtypes.

That brings in the competitor. Roivant’s brepocitinib, a TYK2/JAK1 inhibitor, has an NDA under priority review for dermatomyositis with a PDUFA date in Q3 2026 and a planned launch by the end of September. That setup is covered in the brepocitinib analysis: roughly 50,000 US adults have DM, and brepocitinib is positioned to be the first targeted drug there. If brepocitinib clears the FDA first, argenx enters DM as a challenger with a p=0.1093, not a first mover. That flips the DM commercial story from “first-in-class” to “me-too with a missed endpoint.”

The Franchise Math

Vyvgart is the reason argenx is worth $64.6 billion. Product net sales hit $1.5 billion in Q2 2026, up 60% from $949 million a year earlier, and $2.8 billion for the first half. Full-year 2025 came in at $4.15 billion, up 90%. Annualize the current quarter and you get a $6 billion run rate, which puts argenx at roughly 10.8x forward sales.

Myositis adds something real to that base. The combined IMNM and DM population is roughly 100,000 US patients, and up to 80% of them live with long-term disability. Peak myositis sales for efgartigimod land in the $1 billion to $1.5 billion range, concentrated in IMNM where it is first-in-class and uncontested. At the 3x to 4x peak-sales multiple applied to commercial-stage rare disease assets, that is $3 billion to $6 billion of present value. The market just added $11.7 billion.

So the move overpaid for myositis specifically. What the market actually bought was the validation of argenx’s entire “one mechanism, many indications” thesis. Efgartigimod, an FcRn blocker that clears pathogenic IgG autoantibodies, now works in gMG, CIDP, and myositis, with Sjögren’s disease and systemic sclerosis still in trials. Each win makes the next indication cheaper to de-risk. That is the compounding engine the market is re-rating.

The Competitive Field

argenx does not own the FcRn mechanism alone. Johnson & Johnson’s nipocalimab is the closest rival, and it is already approved in gMG while running Phase 3 programs in Sjögren’s disease and beyond. nipocalimab’s JASMINE lupus data is detailed in the FcRn deep dive: it became the first FcRn blocker to show efficacy in SLE, which matters because it means the mechanism is portable across autoantibody diseases, and argenx and JNJ will be racing each other into every indication.

The difference is focus. argenx is a pure-play FcRn company with one mechanism and a now-proven playbook. JNJ is a $635 billion conglomerate where nipocalimab is one asset filling a Stelara patent-cliff hole. On execution speed for niche autoimmune indications, the pure play wins. That is part of why argenx trades at 10.8x sales while the market treats nipocalimab as a rounding error inside JNJ.

nipocalimab also has a head start in some indications. It won FDA approval in gMG on the back of the Vivacity-MG3 trial, where it delivered a 4.70-point MG-ADL improvement versus 3.25 for placebo at 24 weeks. That makes the FcRn class a two-horse race with a shared mechanism but very different corporate physics. argenx is sprinting through indications; JNJ is managing a portfolio.

argenx is also broadening beyond FcRn. Its $2.2 billion acquisition of Forte Biosciences added the anti-CD122 antibody FB102 with clinical proof-of-concept in vitiligo and celiac disease. That is argenx hedging against the day the FcRn story matures.

What Comes Next

Myositis is not the terminal value of this franchise; it is the fourth turn of a flywheel that still has room to spin. Sjögren’s disease, an autoantibody-driven condition affecting as many as four million Americans, is in Phase 3 for efgartigimod, and a positive readout there would be a larger commercial event than myositis. Systemic sclerosis is earlier but targets a population where no therapy addresses the underlying fibrosis, only the lung complication. Then there is FB102, a second mechanism entirely, which gives argenx a hedge if the FcRn class ever stalls.

The pattern is what matters. Every indication argenx wins makes the next one cheaper to de-risk, because the mechanism, the safety profile, and the commercial infrastructure are already proven. That is the compounding engine a 10.8x multiple is actually pricing. The question is how many of these future readouts the price already assumes will hit.

Risks

The defining risk is concentration. Vyvgart is the entire revenue engine, and argenx is a one-product company wearing a multi-indication costume. A single safety surprise in a chronic, subcutaneous, self-injected drug, or a payer pushback on price, hits the whole franchise at once.

Valuation is not far behind. At 10.8x forward sales, the stock is pricing in flawless execution across Sjögren’s disease and systemic sclerosis before either has read out, and a single miss in those programs would unwind the re-rating as fast as ALKIVIA created it.

The DM label is the near-term catch. If the FDA restricts the myositis indication to IMNM, argenx captures the smaller, rarer half of the market and cedes DM to brepocitinib, pushing peak sales toward the low end of the range.

Verdict

Own argenx for the mechanism, not for this quarter. The ALKIVIA result is real and the IMNM win is durable, but the $11.7 billion reaction overpaid for myositis alone and handed DM to brepocitinib by default. The stock is a hold; do not chase the $1,038 print. If you want to add, wait for a pullback toward the low $900s, the level the stock traded at before the data. That is where the risk-reward stops being priced for perfection.